Why the study?
Does apixaban 2.5 mg twice-daily provide an optimal efficacy and safety balance compared to enoxaparin or warfarin for prevention of venous thromboembolism?
Does apixaban 2.5 mg twice-daily provide an optimal efficacy and safety balance compared to enoxaparin or warfarin for prevention of venous thromboembolism?
A model-based approach identified apixaban 2.5 mg twice-daily as the optimal dose for phase III trials in VTE prevention, demonstrating a better predicted efficacy/safety balance than enoxaparin or warfarin.
No takes yet. Share an insight, caveat, or question.
Apixaban 2.5 mg twice daily maximizes modeled utility for VTE prevention; extends dose-optimization data but leaves phase 3 confirmation open.
Leil et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: